The International Coalition to Eliminate Hepatitis B

Stakeholder’s Consultation

1 November 2017, Sao Paulo

Capucine Penicaud
Meeting Objectives

Provide feedback on ICE-HBV initiative and its scientific priorities, exchange information about current initiatives in HBV cure field, and look for synergies and opportunities for collaboration to accelerate the discovery of curative regimens for CHB

Expected Outcomes

Report back to ICE-HBV governing board meeting on Dec 3rd
ICE-HBV AIM

• Safe, affordable, scalable and effective cure, available to all persons living with CHB.

VISION

• International, independent, research-based and patient-centered forum
Governing Board

(Provisional)

Scientific Working Group

Senior Advisors/Amassadors

Stakeholders Consulting Group

STRUCTURE

Virology

Immunology

Clinical Sciences

Innovative Tools

ICE-HBV
International Coalition to Eliminate HBV
ACTIVITIES

• HBV cure scientific strategy
• Targeted HBV cure research projects
  – cccDNA assay standardization (Virology WG + Gilead)
  – Mathematical modelling (Asian Liver Centre/Doherty/Yellow Warriors)
  – POC diagnostics/assays (Tools WG + Burnet)
• HBV cure research promotion to increase resources for elimination and foster collaborations worldwide.
• Funding Mapping (AVAC)
Provisional Governing Board

• Honorary President Frank Chisari
• Chair Peter Revill (Doherty)
• Co-Chair Fabien Zoulim (ANRS)
• Other Members
  – Joan Block (Hepatitis B Foundation)
  – Massimo Levrero (ANRS)
  – Stephen Locarnini (Doherty)
  – Jake Liang (International HBV meeting)
  – John Tavis (International HBV meeting)
  – Ex-Officio: Program Manager, Capucine Penicaud

To be expanded to representatives from Asia, Africa and Latin America. Gender balance targeted.
(New) Governance Rules

Aims: Ensure inclusivity, visibility and sustainability of ICE-HBV

Key Points:
• Refined governance rules inspired by GAVI
• Step by step expansion of Governing Board to 11 members
• Inclusion of patient community representative
• Creation of an Executive Team for day to day management
• Creation of Senior Advisors/Ambassadors group
Key Stakeholders Consulting Group

Chairs: Veronica Miller (HBV Forum), Ulla Protzer (DZIF), Tim Block (Hepatitis B Foundation)
Alex NG, Bill and Melinda Gates Foundation (Beijing)
Benjamin Cowie, WHO Collaborating Centre for Viral Hepatitis at Doherty Institute
Brian McMahon, World Indigenous Peoples’ Conference on Viral Hepatitis
Christian Bréchot, Institut Pasteur
Chris Muñoz, Yellow Warriors Society Philippines
Dee Lee, Inno Community Development China
Emma Day, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine
François Dabis, ANRS
Helen Tyrell, Hepatitis Australia
Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona
Marc Bultery, Global Hepatitis Programme, HIV/Hepatitis Department, World Health Organization
Maud Lemoine, MRC Gambia/Prolifica
Mehlika Toy, Asian Liver Centre at Stanford University
Michael Ninburg, Hepatitis Education Project
Rajen Koshi, National Institute of Allergy and Infectious Diseases
Raquel Peck, World Hepatitis Alliance
Samuel So, Asian Liver Centre at Stanford University
Stephen Locarnini, CEVHAP
Su Wang, World Hepatitis Alliance
William Phelps, American Cancer Society, Inc.

www.ICE-HBV.org
Acknowledgements

ICE-HBV Governing Board
Frank Chisari
Peter Revill
Fabien Zoulim
Joan Block
Massimo Levrero
Jake Liang
Stephen Locarnini
John Tavis
Capucine Penicaud (Ex-Officio)

ICE-HBV Scientific Working Groups & Stakeholders Group
Contacts

www.ICE-HBV.org

@ ICE_HBV

info@ice-hbv.org
New Policies – Confidentiality

Aims: For ICE-HBV working groups members to share data freely without compromising their publications or intellectual property positions

Key Points:
• Confidentiality acknowledgement letter to be signed by all members.
• Intellectual property stemming from ICE-HBV collaborative research remains with the individual working group members.
• Simple administrative measures: notify confidentiality during meetings and electronic communications.
New Policies – Industry Engagement

Aims: Objectivity & Independence in Bench to Bedside Collaborations

Key Points:
• ICE-HBV considers the private sector a core partner in search for an HBV cure, in addition to academia, community, governments, and civil society.
• After the publication date of ICE-HBV first scientific strategy, ICE-HBV will seek to work with private sector corporations in three ways: as sponsors, as donors, and as participants in activities.
• Principles: transparency, non-exclusivity & no-participation in strategic direction or scientific recommendations.